History 

Significant Events

  
2002
  • ChronVac-C®, a therapeutic vaccine against hepatitis C, is refined into a potential candidate drug.

 

2004
  • The company secures a US patent for a new application of antiviral compound ribavirin.

 

2005
  • Commercial rights secured on a new transgenic mouse model based on ChronVac-C®.

 

2006
  • The company starts clinical development of ChronVac-C® for treating chronic hepatitis C infections alongside US corporation Inovio.
  • To release the value of loss carry-forwards, a property holding was acquired and corporate name changed to Din Bostad Sverige AB. Research operations were transferred to a New Tripep and spun off to shareholders.
  • Wound-healing project ChronSeal was acquired in October and the company was listed on the First North marketplace.
2007
  • Tripep secured a first EU patent on ribavirin as a vaccine adjuvant
  • A phase I/II trial on Tripep's ChronVac-C® vaccine began in the year
  • Tripep has reached an agreement regarding shared development of Tripep's ChronSeal with the Japanese company Kringle Pharma, Inc.
2008
  • Patent application filed for a new antibiotic-free formulation of ChronSeal in collaboration with Kringle Phama, Inc.
  • Tripep successsfully concludes ChronSeal study
  • Preliminary positive results from the first patient in the ongoing ChronVac-C® study